LumiNola/E+ via Getty Images Strong earnings, rising competition and the outlook for AI were key themes on US property and casualty insurers' first quarter earnings calls. The sector posted its strongest first quarter in 25 years for underwriting gains and combined ratio, according to an S&P Global Market Intelligence analysis. Underwriting gains totaled $22.10 billion, and the combined ratio befo...
LumiNola/E+ via Getty Images Strong earnings, rising competition and the outlook for AI were key themes on US property and casualty insurers' first quarter earnings calls. The sector posted its strongest first quarter in 25 years for underwriting gains and combined ratio, according to an S&P Global Market Intelligence analysis. Underwriting gains totaled $22.10 billion, and the combined ratio before policyholder dividends was 89.1%. Piper Sandler analyst Paul Newsome said overall profitability was strong. "When you step back, earnings were pretty good," Newsome said in an interview. "Companies had very high ROEs, even though the weather was normal to heavy in the quarter." Growth stories The Progressive Corp. ( PGR ) continued to grow in the quarter, booking net income of $2.82 billion, total revenue of $22.19 billion and an underwriting profit margin of 13.6%. Net premiums written rose to $23.6 billion, and the Mayfield, Ohio-based insurer added 3.3 million policies in force, bringing its total to 39.57 million. CEO Tricia Griffith said on the company's first quarter earnings call that the current soft market shows no sign of ending, though competition is intensifying "because everyone has great margins" and the competition "is great for consumers." "We think this is a really great opportunity to continue on our growth trajectory and continue to get more and more policyholders to [...] not just to be No. 1 in private passenger auto, but to be the No. 1 destination," Griffith said. Progressive achieved that first goal at the end of March, when it overtook State Farm Mutual Automobile Insurance Co. as the biggest private auto insurer. Progressive's direct premiums written in the 12 months ended March 31 surpassed State Farm's, ending its run as segment leader since 1942. The Allstate Corp. ( ALL ) grew its NPW to $14.63 billion and total revenue to $16.9 billion. Its property-liability business grew policies in force to 38.56 million and posted underwriting income of...
A 68-year-old construction worker is in critical condition after being struck by an electric chain hoist at a Hong Kong government site undergoing drainage replacement works on Wednesday morning. The site on Yen Chow Street in Sham Shui Po is part of the government’s drainage pipe replacement project that spans from Tsuen Wan to West Kowloon. The project is expected to be completed by the end of t...
A 68-year-old construction worker is in critical condition after being struck by an electric chain hoist at a Hong Kong government site undergoing drainage replacement works on Wednesday morning. The site on Yen Chow Street in Sham Shui Po is part of the government’s drainage pipe replacement project that spans from Tsuen Wan to West Kowloon. The project is expected to be completed by the end of this year. Police said they received a report from the site at 8.30am. One of the victim’s colleagues found him unconscious and bleeding from the head. Advertisement The worker was sent to Princess Margaret Hospital in Kwai Chung for immediate surgery. Police, Labour Department and Drainage Services Department officers investigating the accident at the Yen Chow Street site in Sham Shui Po. Photo: Jelly Tse The Association for the Rights of Industrial Accident Victims said he was in critical condition.
When Venkatesham started work on 1 June last year, he had high hopes. "On my very first day, what I thought would be a realistic target for the men's first team would be competing for European places," he said. Even though Tottenham had just finished 17th under Ange Postecoglou, they had won the Europa League, their first trophy since 2008, while the squad was packed with seasoned internationals. ...
When Venkatesham started work on 1 June last year, he had high hopes. "On my very first day, what I thought would be a realistic target for the men's first team would be competing for European places," he said. Even though Tottenham had just finished 17th under Ange Postecoglou, they had won the Europa League, their first trophy since 2008, while the squad was packed with seasoned internationals. But reality quickly struck. "If you'd have asked me a few months after I joined, when I was no longer an outsider, I would have told you the club was in a significantly worse state in some places than I thought," said Venkatesham. "That is absolutely not meant to be a criticism of anyone or anything. It was just what I found. It was very clear that this wasn't some form of turnaround that was required of the club in quite a few areas. It was really a complete reset." Asked to expand on that, Venkatesham said: "If I had to generalise, I would say on the non-football side of the club, in particular around stadium operations and commercial, that the club was and is really strong. "I think if you look at the football side of the club, over a timeframe of five years or so, there has just been an explosion in progress across the Premier League. "I'm not saying that Tottenham didn't improve in that period. But what I can tell you is that when you look at where Tottenham were in many of those areas, compared to where I believe other Premier League clubs are, there was a significant gap. In some areas really quite worryingly so. "I don't think that there was what I would call a relentless obsession with football success. "Our training centre is amazing, one of the best, if not the best in the world. But when you look around, it looks more like a five-star hotel than it does a performance environment. That will change over the summer. "I think there are many areas where the club hasn't got the right level of expertise."
What Happened? Shares of networking chips designer Marvell Technology (NASDAQ: MRVL) jumped 5.7% in the afternoon session after Micron's blowout day signaled that AI-driven chip demand is structurally undersupplied which is bullish news for the equipment makers and foundries that build the capacity. Semiconductor manufacturing equipment (Applied Materials, Lam Research, KLA, ASML) and foundries (T...
What Happened? Shares of networking chips designer Marvell Technology (NASDAQ: MRVL) jumped 5.7% in the afternoon session after Micron's blowout day signaled that AI-driven chip demand is structurally undersupplied which is bullish news for the equipment makers and foundries that build the capacity. Semiconductor manufacturing equipment (Applied Materials, Lam Research, KLA, ASML) and foundries (TSMC, GlobalFoundries) benefit when chip companies announce capacity expansions. Every dollar of additional Micron capex flows to the equipment makers that supply the tools, and every new fab Micron builds is a multi-year revenue stream for the foundries that share processes. UBS estimated Micron will spend $50B+ on capacity over the next 5 years. At industry-average tool intensity, that's billions of equipment orders. Is now the time to buy Marvell Technology? Access our full analysis report here, it’s free. What Is The Market Telling Us Marvell Technology’s shares are extremely volatile and have had 37 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 6 days ago when the stock gained 5.9% on the news that multiple Wall Street analysts raised their price targets on the stock, signaling strong confidence in demand for its artificial intelligence (AI) chips. The wave of positive revisions comes ahead of the company's upcoming earnings report. Analysts from firms including Citigroup, Oppenheimer, Wells Fargo, and Melius Research cited accelerating demand for AI infrastructure and custom processors. In particular, analysts highlighted strong sales of Marvell's Trainium chips to major clients like Amazon as a key growth driver. Oppenheimer forecasts custom chip sales could reach $2 billion in the current year, while other analysts pointed to a significant sales backlog for the Trainium...
Key Points The regulatory landscape in the U.S. has moved a bit in favor of cannabis companies. However, this progress is unlikely to lead to a sustained rally for Tilray Brands. 10 stocks we like better than Tilray Brands › The cannabis industry has been a disappointment. Although Wall Street had high hopes for marijuana stocks toward the end of the last decade, as legal and regulatory progress i...
Key Points The regulatory landscape in the U.S. has moved a bit in favor of cannabis companies. However, this progress is unlikely to lead to a sustained rally for Tilray Brands. 10 stocks we like better than Tilray Brands › The cannabis industry has been a disappointment. Although Wall Street had high hopes for marijuana stocks toward the end of the last decade, as legal and regulatory progress in the market made pot growers more attractive, almost every one of them has significantly underperformed broader equities in recent years. Tilray Brands (NASDAQ: TLRY), a leader in the industry, has been no exception: The company's shares have declined by more than 90% over the past five years. However, some investors hope that recent developments in the U.S. cannabis market could be a turning point for Tilray. Is now a good time to bet on the stock? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » A gift from the government Following an executive order signed by President Trump, products approved by the U.S. Food and Drug Administration that contain marijuana -- as well as medical cannabis products that are legal in certain states -- have been moved from Schedule I to Schedule III. Here's what that means. Under federal law, Schedule I substances are deemed the most addictive while having no recognized medical benefits. Products in the Schedule III category are considered less prone to abuse. This change will make it easier to research potential health-related benefits of marijuana, something that could move the needle for pot growers that operate in the U.S. Tilray is ready to take on this opportunity through its footprints in the U.S. market, where it offers a variety of CBD and hemp-based products, as well as a craft-brewing business. We have seen this movie before It's worth noting that the recent resc...
(RTTNews) - Pets At Home Group Plc (PETS.L) Wednesday reported lower profit in fiscal 2026 with slightly lower revenues. In addition, the firm trimmed dividend, and announced further 50 million pounds share buyback, which will be completed over the next 12 months. Looking ahead for fiscal 2027, the company said it is comfortable with consensus expectations for Group underlying profit before tax, c...
(RTTNews) - Pets At Home Group Plc (PETS.L) Wednesday reported lower profit in fiscal 2026 with slightly lower revenues. In addition, the firm trimmed dividend, and announced further 50 million pounds share buyback, which will be completed over the next 12 months. Looking ahead for fiscal 2027, the company said it is comfortable with consensus expectations for Group underlying profit before tax, currently at 98 million pounds. In the year to date, Pets At Home noted that retail sales growth has accelerated further against tougher comparatives with mid-single digit sales growth and faster volume growth. In the full year, profit before tax fell 28.3 percent to 86.5 million pounds from 120.6 million pounds last year. Earnings per share dropped to 13.6 pence from 18.8 pence a year ago. Group underlying profit before tax was 92.8 million pounds, compared to prior year's 133.0 million pounds. Underlying earnings per share were 14.6 pence, compared to 20.8 pence last year. Group revenue edged down 0.8 percent to 1.450 billion pounds from 1.482 billion pounds in the prior year. Total Group consumer revenue went up 1.0 percent from last year to 1.98 billion pounds. Further, the Board has recommended a final dividend of 2.7 pence per share, taking the total dividend for the year to 7.4 pence per share, down 43.1 percent from 13.0 pence per share last year. The final dividend will be payable on July 15 to shareholders on the register at the close of trading on June 5. For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Dylan Taylor made his first million at 27. Last year, he became a billionaire at 53, after taking his space-holding company, Voyager Technologies, public on the New York Stock Exchange. But don’t expect his two children to inherit all of it. “I’m not a huge believer in generational wealth transfer,” the founder and philanthropist tells Fortune. “I don’t think that’s good for the kids. And I don’t ...
Dylan Taylor made his first million at 27. Last year, he became a billionaire at 53, after taking his space-holding company, Voyager Technologies, public on the New York Stock Exchange. But don’t expect his two children to inherit all of it. “I’m not a huge believer in generational wealth transfer,” the founder and philanthropist tells Fortune. “I don’t think that’s good for the kids. And I don’t think it’s good for society, frankly.” It’s why, like Microsoft cofounder Bill Gates, Taylor has put a hard cap on what his kids will one day receive; “It’s a lot, but it’s eight figures, not nine,” Taylor responds, when asked exactly how much his children can expect to inherit. When you’re worth as much as Taylor, there’s only so much you can spend in one lifetime. Eventually, the conversation turns to what happens to the rest. “At some point, once you have a couple hundred million dollars, you can’t really spend what you have,” Taylor explains. “So it then becomes, how much do you want to give to your kids?” His answer: enough for a safety net, but not enough to remove the need to build something of their own. So far, it seems to be working. His children are now old enough to access those resources, but he says they haven’t touched them. “They want to do things on their own,” Taylor adds. “Which is exactly what you want. That’s what you hope for.” And everything above that eight-figure cap—potentially hundreds of millions, if not more—is going to philanthropic causes he cares about, including Space for Humanity, his nonprofit that sends people to space. This billionaire would rather fund philanthropy The number of billionaires on the planet keeps growing. And Taylor has watched up close (and unimpressed) how his peers approach the question of what to do with money they’ll never spend. “I’ve been in rooms where people are obsessing about deductions and trusts, and how do I get more to my kids,” Taylor says. “It just doesn’t resonate with me.” “I don’t obsess over those kin...
Mohammed Haneefa Nizamudeen/iStock via Getty Images Introduction Vera Therapeutics ( VERA ) has a July 7 PDUFA for atacicept in IgA nephropathy. The molecule has produced good results throughout. In the pivotal phase 3 trial , patients saw a 46% reduction from baseline in 24-hour UPCR and a 42% reduction compared with placebo at week 36, with p<0.0001. There was a 68% reduction in Gd-IgA1 and hema...
Mohammed Haneefa Nizamudeen/iStock via Getty Images Introduction Vera Therapeutics ( VERA ) has a July 7 PDUFA for atacicept in IgA nephropathy. The molecule has produced good results throughout. In the pivotal phase 3 trial , patients saw a 46% reduction from baseline in 24-hour UPCR and a 42% reduction compared with placebo at week 36, with p<0.0001. There was a 68% reduction in Gd-IgA1 and hematuria resolution in 81% of patients. Serious adverse events were seen in 0.5% of atacicept patients versus 5% in placebo patients. The company also produced phase 2b data two years ago. This data went beyond the week-36 proteinuria readout and produced what the company calls the 96-week “quartet” data. These were sustained reductions in UPCR, Gd-IgA1, and hematuria, along with eGFR stabilization. However, the IgAN market has become increasingly competitive. There are now no fewer than five FDA-approved therapies just for IgAN. That makes atacicept’s task cut out for it—not just an FDA approval, atacicept also needs to stand out in terms of label, safety, and especially eGFR data. Atacicept’s Data: Strong, But Not Complete Yet The problem with that last item—eGFR data—is that the 36-week phase 3 trial still doesn’t have long-term eGFR data. It has proteinuria reduction data that is strong enough for approval. However, all five approved molecules and some of those in the pipeline reduce proteinuria. To differentiate itself, atacicept needs more. It already has that data from the phase 2 OLE study. That study did show sustained improvements in UPCR, Gd-IgA1, hematuria, and eGFR—however, it was an open-label study, and the cleaner phase 3 eGFR data will read out only in Q1 2027. Author That makes the July PDUFA just the beginning of the story. Approval may come, but real differentiation will only come with this other data. Peer Comparison: Atacicept is Differentiated, but Not Alone The list of approved and late-stage pipeline molecules I compiled below will show how crowded the...